DNA damage and repair in leukocytes of melanoma patients exposed in vitro to cisplatin

Melanoma Research

Volumn 21, Issue 2, 2011, Pages 99-105

  Shimabukuro, Fernanda ^a   Neto, Cyro F ^a   Sanches Jr , José A ^a   Gattás, Gilka J F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cisplatin; Comet assay; DNA damage; DNA repair; melanoma

Indexed keywords

CISPLATIN;

ADULT; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL DAMAGE; CLINICAL ARTICLE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE; MALE; MELANOMA; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; CISPLATIN; COMET ASSAY; DNA DAMAGE; DNA REPAIR; FEMALE; HUMANS; LEUKOCYTES; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 79952992033     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283426839     Document Type: Article

References (35)

1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445:851-857.
2. Slominski A, Wortsman J, Carlson AJ, Matsuoka LY, Balch CM, Mihm MC. Malignant melanoma. Arch Pathol Lab Med 2001;125:1295-1306.
3. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008;14:1291-1295. (Pubitemid 351413906)
4. Trimmer EE, Essigmann JM. Cisplatin. Essays Biochem 1999;34:191-211. (Pubitemid 129638938)
5. Paz-Elizur T, Brenner DE, Livneh Z. Interrogating DNA repair in cancer risk assessment. Cancer Epidemiol Biomarkers Prev 2005;14:1585-1587. (Pubitemid 40995065)
6. Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995;20:435-439.
7. Kosmider B, Osiecka R, Zyner E, Ochocki J. Comparison between the genotoxicity of cis-Pt (ll) complex of 3-aminoflavone and cis-DDP in lymphocytes evaluated by the comet assay. Drug Chem Toxicol 2005;28:231-244. (Pubitemid 40559527)
8. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-320. (Pubitemid 41130944)
9. Trzeciak AR, Barnes J, Evans MK. A modified alkaline comet assay for measuring DNA repair capacity in human populations. Radiat Res 2008;169:110-121. (Pubitemid 351295098)
10. Burlinson B, Tice RR, Speit G, Agurell E, Brendler-Schwaab SY, Collins AR, et al. Fourth international workgroup on genotoxicity testing: results of the in vivo comet assay workgroup. Mutat Res 2007;627:31-35. (Pubitemid 46091764)
11. McKenna DJ, McKeown SR, McKelvey-Martin VJ. Potential use of the comet assay in the clinical management of cancer. Mutagenesis 2008;23:183-190.
12. Wynne P, Newton C, Ledermann JA, Olaitan A, Mould TA, Hartley JA. Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br J Cancer 2007;97:927-933. (Pubitemid 47519316)
13. Collins AR, Oscoz AA, Brunborg G, Gaivão I, Giovannelli L, Kruszewski M, et al. The comet assay: topical issues. Mutagenesis 2008;23:143-151.
14. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988;175:184-191.
15. Bussab WO, Morettin PA. Basics statistics (Portuguese). São Paulo: Atual; 1987.
16. Neter J, Kutner MH, Nachtsheim CJ, Wasserman W. Applied linear statistical models. Illinois: Richard D. Irwing; 1996.
17. Singer JM, Andrade DF. Analysis of longitudinal data. In: Sen PK, Rao CR, editors. Handbook of statistics. Vol. 18. Amsterdam, North Holland: Bio-Environmental and Public Health Statistics; 2000. pp. 115-160.
18. Marquette A, Bagot M, Bensussan A, Dumaz N. Recent discoveries in the genetics of melanoma and their therapeutic implications. Archivum Immunologiae et Therapiae Experimentalis (Warsz) 2007;55:363-372.
19. Hocker TL, Singh MK, Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol 2008;128:2575-2595.
20. Collins AR. The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 2004;26:249-261. (Pubitemid 41490465)
21. Streffer C. Strong association between cancer and genomic instability. Radiat Environ Biophys 2010;49:125-131.
22. Nadin SB, Vargas-Roig LM, Drago G, Ibarra J, Ciocca DR. DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: a pilot study on the implications in the clinical response to chemotherapy. Cancer Lett 2006;239:84-97. (Pubitemid 43949594)
23. Kopjar N, Garaj-Vrhovac V, Milas I. Assessment of chemotherapy-induced DNA damage in peripheral blood leukocytes of cancer patients using the alkaline comet assay. Teratog Carcinog Mutagen 2002;22:13-30. (Pubitemid 34024285)
24. Palyvoda O, Polańska J, Wygoda A, Rzeszowska-Wolny J. DNA damage and repair in lymphocytes of normal individuals and cancer patients: studies by the comet assay and micronucleus tests. Acta Biochim Pol 2003;50:181-190. (Pubitemid 37034239)
25. Smith TR, Miller MS, Lohman KK, Case LD, Hu JJ. DNA damage and breast cancer risk. Carcinogenesis 2003;24:883-889. (Pubitemid 36748904)
26. Sánchez-Suárez P, Ostrosky-Wegman P, Gallegos- Hernández F, Peñarroja-Flores R, Toledo-García J, Bravo JL, et al. DNA damage in peripheral blood lymphocytes in patients during combined chemotherapy for breast cancer. Mutat Res 2008;640:8-15.
27. Rondón S, Rangel N, Ramírez S. Cytogenetic study in peripheral blood of melanoma patients. Invest Clin 2009;50:173-186.
28. Blasiak J, Kowalik J, Malecka-Panas E, Drzewoski J, Wojewódzka M. DNA damage and repair in human lymphocytes exposed to three anticancer platinum drugs. Teratog Carcinog Mutagen 2000;20:119-131. (Pubitemid 30328997)
29. Olive PL, Banáth JP. Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytometry B Clin Cytom 2009;76:79-90.
30. Clingen PH, Wu JY, Miller J, Mistry N, Chin F, Wynne P, et al. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem Pharmacol 2008;76:19-27.
31. Braybrooke JP, Houlbrook S, Crawley JE, Propper DJ, O'Byrne KJ, Stratford IJ, et al. Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen. Cancer Chemother Pharmacol 2000;45:111-119. (Pubitemid 30090241)
32. Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, McHugh P, et al. Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly (ADP-ribose) polymerase-1. Clin Cancer Res 2005;11:3402-3409. (Pubitemid 40627893)
33. Leibeling D, Laspe P, Emmert S. Nucleotide excision repair and cancer. J Mol Histol 2006;37:225-238. (Pubitemid 44795626)
34. Fichtinger-Schepman AM, Van der Velde-Visser SD, Van Dijk-Knijnenburg HC, Van Oosterom AT, Baan RA, Berends F. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res 1990;50:7887-7894.
35. Almeida GM, Duarte TL, Steward WP, Jones GD. Detection of oxaliplatininduced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay. DNA Repair (Amst) 2006;5:219-225. (Pubitemid 43069522)